NantHealth
- Home ›
- US ›
- Healthcare
NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The last earnings update was 21 days ago. More info.
Add to Portfolio Compare Print
- NantHealth has significant price volatility in the past 3 months.
NH Share Price and Events
7 Day Returns
1 Year Returns
NH Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| NantHealth (NH) | -5.3% | -15.6% | 24.4% | -76.6% | - | - |
| US Healthcare Services | -2.8% | 0.1% | 6.1% | 21.9% | 52.5% | 52.6% |
| US Market | -0.3% | 2% | 8.5% | 7% | 37.7% | 46.8% |
1 Year Return vs Industry and Market
- NH underperformed the Healthcare Services industry which returned 21.9% over the past year.
- NH underperformed the Market in United States of America which returned 7% over the past year.
NH Value
Is NantHealth undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
NantHealth
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for NantHealth.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 2 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 14.7% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Healthcare Services Unlevered Beta | Simply Wall St/ S&P Global | 1.21 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.213 (1 + (1- 21%) (232.24%)) |
2.634 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
2 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (2 * 5.96%) |
14.65% |
Discounted Cash Flow Calculation for NasdaqGS:NH using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for NantHealth is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 14.65%) |
|
|---|---|---|---|
| 2019 | 45.55 | Analyst x1 | 39.73 |
| 2020 | 61.42 | Analyst x1 | 46.73 |
| 2021 | 94.56 | Analyst x1 | 62.75 |
| 2022 | 130.40 | Analyst x1 | 75.47 |
| 2023 | 174.35 | Analyst x1 | 88.02 |
| 2024 | 211.01 | Est @ 21.02% | 92.91 |
| 2025 | 243.79 | Est @ 15.54% | 93.63 |
| 2026 | 272.30 | Est @ 11.69% | 91.21 |
| 2027 | 296.82 | Est @ 9% | 86.72 |
| 2028 | 317.96 | Est @ 7.12% | 81.03 |
| Present value of next 10 years cash flows | $758.19 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $317.96 × (1 + 2.73%) ÷ (14.65% – 2.73%) |
$2,740.31 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $2,740.31 ÷ (1 + 14.65%)10 |
$698.33 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $758.19 + $698.33 |
$1,456.52 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $1,456.52 / 109.92 |
$13.25 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $13.25 |
| Current discount | Discount to share price of
$0.79
= -1 x ($0.79 - $13.25) / $13.25 |
94.1% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- NantHealth's share price is below the future cash flow value, and at a moderate discount (> 20%).
- NantHealth's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for NantHealth's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
NantHealth's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $-1.74 |
| NasdaqGS:NH Share Price ** | NasdaqGS (2019-04-18) in USD | $0.79 |
| United States of America Healthcare Services Industry PE Ratio | Median Figure of 14 Publicly-Listed Healthcare Services Companies | 76.25x |
| United States of America Market PE Ratio | Median Figure of 3,081 Publicly-Listed Companies | 18.18x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of NantHealth.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:NH Share Price ÷ EPS (both in USD) = 0.79 ÷ -1.74 |
-0.45x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- NantHealth is loss making, we can't compare its value to the US Healthcare Services industry average.
- NantHealth is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
NantHealth's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -0.45x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts |
48.4%per year |
| United States of America Healthcare Services Industry PEG Ratio | Median Figure of 13 Publicly-Listed Healthcare Services Companies | 2.67x |
| United States of America Market PEG Ratio | Median Figure of 2,109 Publicly-Listed Companies | 1.56x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for NantHealth, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
NantHealth's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $0.03 |
| NasdaqGS:NH Share Price * | NasdaqGS (2019-04-18) in USD | $0.79 |
| United States of America Healthcare Services Industry PB Ratio | Median Figure of 34 Publicly-Listed Healthcare Services Companies | 4.18x |
| United States of America Market PB Ratio | Median Figure of 5,184 Publicly-Listed Companies | 1.91x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:NH Share Price ÷ Book Value per Share (both in USD) = 0.79 ÷ 0.03 |
30.37x |
* Primary Listing of NantHealth.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- NantHealth is overvalued based on assets compared to the US Healthcare Services industry average.
Value checks
We assess NantHealth's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check) NantHealth has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
NH Future Performance
How is NantHealth expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- NantHealth's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- NantHealth's earnings growth is expected to exceed the United States of America market average.
- NantHealth's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:NH Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts | 48.4% |
| NasdaqGS:NH Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts | 26.5% |
| United States of America Healthcare Services Industry Earnings Growth Rate | Market Cap Weighted Average | 22.2% |
| United States of America Healthcare Services Industry Revenue Growth Rate | Market Cap Weighted Average | 11.5% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.4% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 347 | 188 | 25 | 1 |
| 2022-12-31 | 241 | 143 | -25 | 1 |
| 2021-12-31 | 176 | 107 | -61 | 1 |
| 2020-12-31 | 124 | 26 | -93 | 2 |
| 2019-12-31 | 100 | 13 | -105 | 2 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 89 | -30 | -190 |
| 2018-09-30 | 89 | -34 | -164 |
| 2018-06-30 | 88 | -50 | -89 |
| 2018-03-31 | 90 | -68 | -125 |
| 2017-12-31 | 87 | -81 | -131 |
| 2017-09-30 | 82 | -92 | -157 |
| 2017-06-30 | 81 | -84 | -161 |
| 2017-03-31 | 80 | -65 | -138 |
| 2016-12-31 | 80 | -71 | -145 |
| 2016-09-30 | 83 | -74 | -131 |
| 2016-06-30 | 77 | -85 | -128 |
| 2016-03-31 | 66 | -91 | -110 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
All data from NantHealth Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 0.21 | 0.21 | 0.21 | 1.00 |
| 2022-12-31 | -0.22 | -0.22 | -0.22 | 1.00 |
| 2021-12-31 | -0.53 | -0.53 | -0.53 | 1.00 |
| 2020-12-31 | -0.66 | -0.50 | -0.82 | 2.00 |
| 2019-12-31 | -0.74 | -0.53 | -0.94 | 2.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | -1.74 |
| 2018-09-30 | -1.51 |
| 2018-06-30 | -0.81 |
| 2018-03-31 | -1.10 |
| 2017-12-31 | -1.13 |
| 2017-09-30 | -1.31 |
| 2017-06-30 | -1.32 |
| 2017-03-31 | -1.18 |
| 2016-12-31 | -1.30 |
| 2016-09-30 | -1.24 |
| 2016-06-30 | -1.29 |
| 2016-03-31 | -0.20 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if NantHealth will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess NantHealth's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
NantHealth has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
NH Past Performance
How has NantHealth performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- NantHealth does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare NantHealth's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare NantHealth's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
All data from NantHealth Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 89.46 | -190.43 | 70.76 | 20.92 |
| 2018-09-30 | 88.90 | -163.77 | 76.92 | 24.69 |
| 2018-06-30 | 88.37 | -89.36 | 77.44 | 27.60 |
| 2018-03-31 | 89.84 | -125.25 | 78.28 | 30.09 |
| 2017-12-31 | 86.68 | -131.40 | 74.98 | 33.86 |
| 2017-09-30 | 82.22 | -157.25 | 70.58 | 35.84 |
| 2017-06-30 | 81.13 | -160.63 | 75.09 | 38.05 |
| 2017-03-31 | 80.06 | -137.84 | 95.32 | 45.54 |
| 2016-12-31 | 80.40 | -145.48 | 105.26 | 47.31 |
| 2016-09-30 | 82.96 | -130.96 | 105.50 | 38.98 |
| 2016-06-30 | 76.71 | -127.52 | 101.61 | 36.04 |
| 2016-03-31 | 66.01 | -109.86 | 80.00 | 25.14 |
| 2015-12-31 | 46.18 | -61.73 | 55.72 | 14.25 |
| 2015-09-30 | 47.83 | -83.84 | 66.07 | 20.82 |
| 2015-06-30 | 43.35 | -90.57 | 61.60 | 17.93 |
| 2015-03-31 | 38.63 | -85.86 | 53.18 | 17.32 |
| 2014-12-31 | 33.92 | -84.43 | 46.21 | 16.98 |
| 2013-12-31 | 26.72 | -40.93 | 35.31 | 10.75 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if NantHealth has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if NantHealth has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if NantHealth improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess NantHealth's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
NantHealth has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
NH Health
How is NantHealth's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up NantHealth's finances.
The net worth of a company is the difference between its assets and liabilities.
- NantHealth is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- NantHealth's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from NantHealth Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 2.83 | 200.48 | 18.31 |
| 2018-09-30 | 51.20 | 199.16 | 22.84 |
| 2018-06-30 | 148.12 | 197.89 | 29.41 |
| 2018-03-31 | 171.04 | 196.65 | 46.39 |
| 2017-12-31 | 193.30 | 195.46 | 61.66 |
| 2017-09-30 | 208.75 | 194.30 | 73.49 |
| 2017-06-30 | 299.82 | 193.18 | 92.67 |
| 2017-03-31 | 369.52 | 192.09 | 124.89 |
| 2016-12-31 | 411.59 | 191.04 | 157.57 |
| 2016-09-30 | 451.14 | 112.67 | 75.80 |
| 2016-06-30 | 485.12 | 112.67 | 95.31 |
| 2016-03-31 | 202.58 | 152.67 | 24.63 |
| 2015-12-31 | 185.01 | 0.00 | 7.23 |
| 2015-09-30 | |||
| 2015-06-30 | 235.12 | 0.00 | 53.50 |
| 2015-03-31 | 64.80 | 34.50 | 225.57 |
| 2014-12-31 | 64.80 | 34.50 | 225.57 |
| 2013-12-31 | 20.66 | 30.57 | 17.02 |
- NantHealth's level of debt (7081.5%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (147.2% vs 7081.5% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- NantHealth has less than a year of cash runway based on current free cash flow.
- NantHealth has less than a year of cash runway if free cash flow continues to reduce at historical rates of -19.9% each year.
Financial health checks
We assess NantHealth's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) NantHealth has a total score of 1/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
NH Dividends
What is NantHealth's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
NantHealth
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate NantHealth's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate NantHealth's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Global Healthcare Services Industry Average Dividend Yield | Market Cap Weighted Average of 15 Stocks | 1.3% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2009 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as NantHealth has not reported any payouts.
- Unable to verify if NantHealth's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess NantHealth's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can NantHealth afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) NantHealth has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
NH Management
CEO
| COMPENSATION | $0 |
| AGE | 65 |
| TENURE AS CEO | 8.8 years |
CEO Bio
Dr. Patrick Soon-Shiong, M.D., FRCS (C), FACS, MBBCh, MSS, FRCS (C), is an Owner of Los Angeles Times Communications, LLC. Dr. Soon-Shiong is a physician, surgeon and scientist, invented and developed the revolutionary drug Abraxane. He serves as Chief Executive Officer and as Chairman of NantHealth, Inc. since July 2010 and Director since 2010. Dr. Soon-Shiong served as the Interim Chief Executive Officer of Verity Health System of Califo until January 4, 2018. From 1997- 2010, Dr. Soon-Shiong served as Founder, Chairman and CEO of global pharmaceutical companies American Pharmaceutical Partners and Abraxis BioScience. In 2011, Dr. Soon-Shiong formed NantWorks. He serves as Chief Executive Officer and Chairman of the board of directors of NantWorks. In January 2016, Dr. Soon-Shiong announced the formation of Cancer Moonshot 2020. Dr. Soon-Shiong serves as Chairman and CEO of NantKwest (NK). Dr. Soon-Shiong is Chairman of the Chan Soon-Shiong Family Foundation and Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine. He co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. Dr. Patrick Soon-Shiong is the Founder of Nant Capital, LLC, NantWorks and NantHealth. He has also spearheaded a cancer moonshot initiative - separate from the effort affiliated with former Vice President Joe Biden - named Cancer Breakthroughs 2020, in 2016 with his firm NantHealth. Dr. Soon-Shiong was a Director of Tronc until April 2017. He is an Adjunct Professor of Surgery at UCLA, and a visiting Professor at the Imperial College of London and Dartmouth College. He is the Executive Director of the UCLA Wireless Health Institute and a board member of the California Telehealth Network. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. In April 2016, Dr. Soon-Shiong received the Franklin Institute Award for his visionary leadership and commitment to advancing medical and scientific research and bringing new treatment options to cancer patients. Also in April 2016, Dr. Soon-Shiong was honored at the Vatican and received the 2016 Pontifical Key Visionary Award. The award recognized Dr. Soon-Shiong’s contribution to medical innovation and visionary leaders who change the course of history and reduce suffering on a global scale by blending visionary thinking with real action. Dr. Patrick Soon-Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. Dr. Patrick Soon-Shiong is a board certified surgeon and a fellow of the American College of Surgeons and of the Royal College of Physicians and Surgeons of Canada.
CEO Compensation
- Insufficient data for Patrick to compare compensation growth.
- Patrick's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the NantHealth management team in years:
- The average tenure for the NantHealth management team is less than 2 years, this suggests a new team.
Management Team
Patrick Soon-Shiong
Founder
65
8.8 yrs
Ron Louks
COO & Director
$3M
53
1.9 yrs
Bob Petrou
Interim Chief Financial Officer
46
0.6 yrs
Brandon Villery
VP, General Counsel & Corporate Secretary
1.5 yrs
Charles Hunt
Vice President of Marketing
1.5 yrs
Maureen Becker
Vice President of Human Resources
1.2 yrs
Bobby Reddy
Chief Medical Officer
1.9 yrs
Greg Dunko
Senior Vice President of Product & Program Management
1.5 yrs
Keith Krebs
Senior Vice President of Client Services
1.5 yrs
Chris House
Senior Vice President of Product Development
1.5 yrs
Board of Directors Tenure
Average tenure and age of the NantHealth board of directors in years:
- The average tenure for the NantHealth board of directors is less than 3 years, this suggests a new board.
Board of Directors
Patrick Soon-Shiong
Founder
65
8.8 yrs
Ron Louks
COO & Director
$3M
53
0.8 yrs
Michael Sitrick
Director
$227K
71
2.9 yrs
Michael Blaszyk
Director
$232K
66
2.9 yrs
Kirk Calhoun
Director
$222K
74
2.9 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess NantHealth's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) NantHealth has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
NH News
Simply Wall St News
Do Insiders Own Lots Of Shares In NantHealth, Inc. (NASDAQ:NH)?
Generally speaking, as a company grows, institutions will increase their ownership. … Taking a look at our data on the ownership groups (below), it's seems that. … We can zoom in on the different ownership groups, to learn more about NH
Simply Wall St - – Full articleHow Does NantHealth, Inc. (NASDAQ:NH) Affect Your Portfolio Volatility?
(NASDAQ:NH), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.
Simply Wall St - – Full articleIs There An Opportunity With NantHealth Inc's (NASDAQ:NH) 22.17% Undervaluation?
by taking the foreast future cash flows of the company and discounting them back to today's value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model
Simply Wall St - – Full articleNantHealth Inc (NASDAQ:NH): Time For A Financial Health Check
NantHealth Inc (NASDAQ:NH) is a small-cap stock with a market capitalization of US$309.00m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … So, understanding the company's financial health becomes
Simply Wall St - – Full articleIs Now The Right Time To Invest In Healthcare And NantHealth Inc (NASDAQ:NH)?
is a healthcare company operating in an industry,. … The healthcare tech industry, in particular, is presented with an array of technology to progress innovation clinically and cost-effectively … Healthcare analysts are forecasting for the entire industry,
Simply Wall St - – Full articleWhat does NantHealth Inc's (NASDAQ:NH) Balance Sheet Tell Us About Its Future?
While small-cap stocks, such as NantHealth Inc (NASDAQ:NH) with its market cap of US$358.34m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Companies operating in the Healthcare Services industry,
Simply Wall St - – Full articleNantHealth Inc (NASDAQ:NH): Time For A Financial Health Check
In the previous 12 months, NH's rose by about US$191.04M made up of current and long term debt. … Moving onto cash from operations, its operating cash flow is not yet significant enough to calculate a meaningful cash-to-debt ratio, indicating that operational efficiency is something we’d need to take a look at. … Maintaining a high level of debt, while revenues are still below costs, can be dangerous as liquidity tends to dry up in unexpected downturns.Next Steps: NH’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.
Simply Wall St - – Full articleWhat Investors Should Know About NantHealth Inc's (NH) Financial Strength
We can test the impact of these adverse events by looking at whether cash from its current operations can pay back its current debt obligations. … Its cash flow coverage of less than a quarter of debt means that operating efficiency could be an issue. … Furthermore, its cash flow coverage of less than a quarter of debt means that operating efficiency could also be an issue.
Simply Wall St - – Full articleNH Company Info
Description
NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice. The company’s products include GPS Cancer, a molecular profile that integrates whole genome sequencing of tumor and normal germline samples, as well as whole transcriptome sequencing; GPS Cancer Report, a GPS cancer solution; GPS in rare diseases and chronic illnesses; Liquid GPS, a blood-based molecular test; and Eviti, a decision support solution. It also provides Web-based and mobile software solutions, such as Device Connectivity Suite, a device connectivity and near real-time biometric software and hardware suite; DeviceConX, a device data normalization software; HBox, an Internet of Medical Things and Internet of Things hardware hub; and VitalsConX, a tablet-optimized application. In addition, NantHealth, Inc. offers NaviNet Open, a payer-provider collaboration platform comprising plan central, eligibility and benefit, claims status inquiry, claims management, referral, authorization, document exchange, and AllPayer services; and cloud-based computing, storage, and transport infrastructure-as-a-service solutions. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was founded in 2010 and is headquartered in Culver City, California. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.
Details
| Name: | NantHealth, Inc. |
| NH | |
| Exchange: | NasdaqGS |
| Founded: | 2010 |
| $86,321,468 | |
| 109,921,646 | |
| Website: | http://nanthealth.com |
| Address: |
NantHealth, Inc. 9920 Jefferson Boulevard, Culver City, California, 90232, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | NH | Common Shares | Nasdaq Global Select | US | USD | 02. Jun 2016 | |
| DB | NEL | Common Shares | Deutsche Boerse AG | DE | EUR | 02. Jun 2016 |
Number of employees
Current staff
Industry
| Health Care Technology | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/22 00:36 |
| End of day share price update: | 2019/04/18 00:00 |
| Last estimates confirmation: | 2019/04/18 |
| Last earnings filing: | 2019/04/01 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
